1. Kessler, D. A., Siegel, J. P., Noguchi, P. D, et al. (1993). Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N. Engl. ]. Med. 329, 1169-1173.
  2. Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (January 2001). Available at
  3. Center for Drug Evaluation and Research. (September 1989). "Guideline for Drug Master Files."
  4. Food and Drug Administration, Center for Biologies Evaluation and Research (March 1998). "Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy." Available at
  5. (1993). "Points to Consider in the Characterization of Cell lines Used to Produce Biologicals." Available at
  6. Federal Register Notice of Availability (September 9, 1998). "International Conference on Harmonisation: Guidance on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin; Availability." 63 FR 51074.
  7. WBF and CBER websites for Adenovirus Reference Material Working Group, Bid proposals and meeting minutes/transcripts and
  8. "Biologies Response Modifiers Advisory Committee Meeting, Nov. 16-17, 2000." Transcripts available at
  9. "Biologies Response Modifiers Advisory Committee Meeting April 5-6, 2001." Transcripts available at
  10. "Biologies Response Modifiers Advisory Committee Meeting Oct. 24-26,2001." Transcripts available at
  11. Shabram, P., and Aguilar-Cordova, E. (2000). Multiplicity of infection/multiplicity of confusion. Mol. Ther. 2, 420-421.
  12. Hutchins, B., Sajjadi, N., Seaver, S., Shepherd, A., Bauer, S. R., Simek, S., Carson, K., and Aguilar-Cordova, E. (2000). Working toward an adenoviral vector testing standard. Mol. Ther. 2, 532-534.
  13. International Conference on Harmonisation (July 1997). "Guidance for Industry. S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals." Available at http://www.
  14. Crystal, R. G., McElvaney, N. G., Rosenfeld, M. A., Chu, C. S., Mastrangeli, A., Hay, J. G., Brody, S. L., Jaffe, H. A., Eissa, N. T., and Danel, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51.
  15. Recombinant DNA Advisory Committee Meeting htm
  16. Pilaro, A. M., and Serabian, M. A. (1999). Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. 27, 4-7.
  17. International Conference on Harmonisation. "Guidance for Industry. E6: Good Clinical Practice: Consolidated Guidance." Available at
  18. International Congress on Harmonisation. "Guidance for Industry. E3: Structure and Content of the Final Study Report." Available at
  19. International Congress on Harmonisation. "The Common Technical Document." Available at
  20. Kessler, D. A. (1993). MedWatch: The new FDA medical products reporting program Am. J. Hosp. Pharm. 50, 1151-1152.
  21. "Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Industry Products. Interim Rule." Available at cd0030.pdf.
  22. International Conference on Harmonisation. "Ell: Clinical Investigation of Medicinal Products in the Pediatric Population." Available at
  23. Wittes, J. (1993). Behind closed doors: The data monitoring board in randomized clinical trials. Stat. Med. 12,419-424.
  24. Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S. H., Woo, S. L., and Grossman, R. G. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1, 195-203.
  25. Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., and Verma, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. USA 95, 1377-1382.
  26. Recombinant DNA Advisory Committee. "Minutes of Symposium and Meeting, December 8-10, 1999." Available at:
  27. "Testing for Replication Competent Retrovirus in Retroviral Based Gene Therapy Products and During Follow up of Patients in Clinical Trials using Retroviral Vectors, October 18, 2000." Available at
  28. International Conference on Harmonisation. "Guidance for Industry. ElO: Choice of Control." Available at
  29. Fleming, T. R. (1994). Surrogate markers in AIDS and cancer trials Stat. Med. 13, 1423-1435.
  30. Fleming, T. R., and DeMets, D. L. (1996). Surrogate Endpoints in Clinical Trials: Are We Being Misled? Ann. Intern. Med. 125, 605-613.
  31. "Guidance for Industry: Providing Clinical Evidence of Effectiveness, May 1998." Available at
  32. NIH Report. Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee (2002). Hum. Gene Ther. 13, 3-13.
  33. Warning Letters and warning-letters.
  34. Notice of Intent at
  35. Mcintosh, K. (1990). Diagnositc virology. In "Fields Virology" (B.N. Fields and D.M. Knipe, Eds.), 2nd ed., Raven Press, Chap. 17, pp. 383-410. New York.
  36. Wagner, R. (1990). Rhabdoviridae and their replication. In "Fields Virology" (B. N. Fields and D. M. Knipe, Eds.), 2nd ed., Raven Press, Chap. 31, pp. 867-883. New York.


Was this article helpful?

0 0

Post a comment